Cutting-Edge Concepts in HIV Care: PrEP

In this episode, Paul E. Sax, MD, discusses the latest recommendations and options for HIV pre-exposure prophylaxis (PrEP), including:

• CDC PrEP guideline 2021 updates for oral PrEP
• The ANRS IPERGAY study: on-demand oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) PrEP in men who have sex with men who are at high risk for HIV infection
• A review of the HPTN 083 and 084 studies: efficacy and safety of long-acting (LA) injectable cabotegravir (CAB) vs daily oral FTC/TDF for PrEP
• 1-year follow-up after unblinding for HPTN 083 and 084
• LA CAB for PrEP: monitoring and safety
• Stopping LA CAB for PrEP

Presenter: 

Paul E. Sax, MD
Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Link to full program:
https://bit.ly/3VIsDTg

Follow along with the slides at:
https://bit.ly/3Gh9AKG

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.